Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours

Amina Fouad Farag

Status: Completed

Conditions: Carcinoma Ex Pleomorphic Adenoma of Salivary Glands; Pleomorphic Adenoma of Salivary Glands

Treatments: Diagnostic Test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction; Diagnostic Test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction

Study type: Observational

Funder types: Other

Identifiers

NCT04907422

RECO6U/5-2018

Details and patient eligibility

About

Nano-based diagnostic tool can provide promising highly sensitive, specific biomarker for early detection and treatment of salivary gland tumours compared to non-conjugated biomarkers and in turn improves patient prognosis and outcome.

Full description

Cancer stem cells form a small subset of highly tumorigenic cells within the bulk of the tumours which mainly responsible for initiation, invasion, rapid growth, metastasis and therapeutic resistance in different types of human cancers. Nowadays, nanotechnology has increasing attention in multi-disciplinary research fields. Conjugated gold nanoparticles are widely used as biomarkers and bio-delivery vehicles in the medicine as well as early and advanced cancer detection and treatment. The current work aimed to introduce a novel diagnostic and prognostic approach in early detection of cancer stem cells in salivary gland tumours using gold nanoparticles conjugated to CD24 (CD24-Gold Nanocomposite).

Enrollment: 60 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Benign PA of major and minor salivary glands (PA group),
• CXPA of major and minor salivary glands (CXPA group).
• Border of excision biopsy of mucocele in the lip mucosa of healthy individuals used as normal controls (Control group).
• Surgical excision of tumors with no preoperative chemotherapy or radiotherapy. For parotid tumours partial or total parotidectomy, Surgery was performed with or without facial nerve preservation and the later was carried out commonly when the nerve was involved by tumour. For tumours in the other glands, complete surgical excision with the involved gland and the suspicious adjacent structures was performed.

Exclusion criteria

• All epithelial origin salivary gland tumours other than PA and CXPA.
• All mesenchymal origin salivary gland tumours.
• All inflammatory and cystic lesions of salivary glands.
• Metastasis in salivary glands.
• Patients received preoperative chemotherapy or radiotherapy.

Trial design

60 participants in 3 patient groups

CXPA group

Description:

carcinoma ex pleomorphic adenoma of major and minor salivary glands.

Treatment:

Diagnostic Test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction

Diagnostic Test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction

PA group

Description:

Benign pleomorphic adenoma of major and minor salivary glands.

Treatment:

Diagnostic Test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction

Diagnostic Test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction

Control group

Description:

normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.

Treatment:

Diagnostic Test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction

Diagnostic Test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction